BioCryst Pharmaceuticals Q4 2025 Earnings Preview
Source: SeekingAlpha
2026-02-25 09:56:42 ET
More on BioCryst Pharmaceuticals
- BioCryst: The $700 Million Pivot From Oral Convenience To Injectable
- BioCryst: A Changed And Interesting Thesis For 2026
- 44th Annual J.P. Morgan Healthcare Conference
- BioCryst Pharmaceuticals reports prelim 2025 ORLADEYO revenue, provides 2026 guidance
- BioCryst wins FDA approval for Orladeyo oral pellets
Read the full article on Seeking Alpha
For further details see:
BioCryst Pharmaceuticals Q4 2025 Earnings Preview
BioCryst Pharmaceuticals Inc.
NASDAQ: BCRX
BCRX Trading
3.24% G/L:
$8.595 Last:
2,344,045 Volume:
$8.48 Open:
BCRX Latest News
February 26, 2026 07:00:00 am
BioCryst Reports Full Year 2025 Financial Results and Provides Business Update
BCRX Stock Data
$1,391,931,498
199,991,369
0.01%
88
N/A
Biotechnology & Life Sciences
Healthcare
US
Durham
